BioXcel Therapeutics Inc

NASDAQ:BTAI  
16.75
-0.68 (-3.90%)
Products

Bioxcel Therapeutics Announces Extension Of FDA Review Period Of Its NDA For Bxcl501 For The Acute Treatment Of Agitation Associated With Schizophrenia And Bipolar Disorders

Published: 12/01/2021 12:36 GMT
BioXcel Therapeutics Inc (BTAI) - Bioxcel Therapeutics Announces Extension of FDA Review Period of Its NDA for Bxcl501 for the Acute Treatment of Agitation Associated With Schizophrenia and Bipolar Disorders.
Bioxcel Therapeutics Inc - PDUFA Date Extended by Three Months to April 5, 2022 for NDA Review of Bxcl501.
Bioxcel Therapeutics Inc - PDUFA Date Extended by Three Months to April 5, 2022.
Bioxcel Therapeutics Inc - No Additional Data Requested Following Meeting With FDA.